Search results
Showing 76 to 90 of 365 results for heart failure
ID CG187/01 Question Dopamine: In people with acute heart failure, congestion and worsening renal function, does the addition of low‑dose
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
View quality statements for QS99Show all sections
Sections for QS99
- Quality statements
- Quality statement 1: Assessment of left ventricular function
- Quality statement 2: Referral for cardiac rehabilitation
- Quality statement 3: Communication with primary care
- Quality statement 4: Cardiac rehabilitation – assessment appointment
- Quality statement 5 (developmental): Options for cardiac rehabilitation
- Update information
- About this quality standard
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
into efficacy of extracorporeal membrane oxygenation (ECMO) for acute heart failure. This should include clear documentation of patient...
evidence on cardiac contractility modulation device implantation for heart failure raises no major safety concerns. However, the...
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline sets out an antimicrobial prescribing strategy for community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.
Transient loss of consciousness ('blackouts') in over 16s (QS71)
This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.
View quality statements for QS71Show all sections
Sections for QS71
- Quality statements
- Quality statement 1: Initial assessment – recording the event, clinical history and physical examination
- Quality statement 2: Initial assessment – 12-lead electrocardiogram (ECG)
- Quality statement 3: Urgent specialist cardiovascular assessment within 24 hours of the initial assessment
- Quality statement 4: Initial assessment – unnecessary use of electroencephalogram (EEG)
- Quality statement 5: Driving advice
- Quality statement 6: Specialist cardiovascular investigation – ambulatory electrocardiogram (ECG)
- Update information
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
In development [GID-TA11561] Expected publication date: 13 August 2025
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
efficacy of permanent His-bundle pacemaker implantation for treating heart failure is inadequate in quality and quantity.Therefore, this...
Evidence-based recommendations on implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home